FDA Floats Eliminating Multi-Ingredient Pediatric Cold Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Consumer Healthcare Products Association, FDA agree labeling for OTC cough/cold drugs should indicate use is not safe for children under 2 years old, while Center for Drug Evaluation and Research cites “heightened risk of overdose due to concurrent therapy with multi-ingredient” products.
You may also be interested in...
Warnings Note Disease Treatment Studies Placed Too Close To Supplements For US FDA’s Comfort
Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.
OTC Decisions November-December: GSK Labels For Nexium Promotion, Voltaren 2-Pack Approved
Approvals by FDA also include revised container and consumer information labeling for J&J's Men’s Rogaine to align with labeling for Women’s Rogaine; bonus-pack labeling for Bayer AG’s Aleve; and
J&J CEO: COVID-19 ‘Demonstrated Importance of Self-Care Overall’
During JP Morgan conference, Alex Gorsky suggests responding to pandemic is changing health care, including businesses providing pharmaceuticals, medical technologies, nutritionals and other necessary products.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: